LPL Financial
VERV

LPL Financial’s Verve Therapeutics VERV Stock Holding History

LPL Financial’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,597
Closed -$141K – 5995
2025
Q2 		$141K Buy
+12,597
New +$71.8K ﹤0.01% 5186
2025
Q1 		– Sell
-37,629
Closed -$212K – 5528
2024
Q4 		$212K Buy
37,629
+18,282
+94% +$103K ﹤0.01% 4775
2024
Q3 		$93.6K Buy
19,347
+6,308
+48% +$36.6K ﹤0.01% 4906
2024
Q2 		$63.6K Sell
13,039
-31,324
-71% -$197K ﹤0.01% 4810
2024
Q1 		$589K Buy
+44,363
New +$588K ﹤0.01% 3640

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

LPL Financial's VERV Position: Q3 2025 in Review

LPL Financial sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 12,597 shares — an estimated $141K sold.

LPL Financial first reported a position in VERV in Q1 2024 and held it in 5 quarters. The position peaked at $589K in Q1 2024. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • LPL Financial reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • LPL Financial sold 12,597 Verve Therapeutics shares in Q3 2025, an estimated $141K.
  • LPL Financial first reported a position in Verve Therapeutics in Q1 2024 and held it in 5 quarters.
  • LPL Financial's Verve Therapeutics position peaked at $589K in Q1 2024.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on LPL Financial's 13F filing for Q3 2025, filed 12 Nov 2025.